See more : QYOU Media Inc. (QYOUF) Income Statement Analysis – Financial Results
Complete financial analysis of Theriva Biologics, Inc. (TOVX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theriva Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chengdu CORPRO Technology Co., Ltd. (300101.SZ) Income Statement Analysis – Financial Results
- InnoPharmax Inc. (4172.TWO) Income Statement Analysis – Financial Results
- Boai NKY Medical Holdings Ltd. (300109.SZ) Income Statement Analysis – Financial Results
- Next 15 Group plc (NFG.L) Income Statement Analysis – Financial Results
- Opdenergy Holding, S.A. (OPDE.MC) Income Statement Analysis – Financial Results
Theriva Biologics, Inc. (TOVX)
About Theriva Biologics, Inc.
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.16M | 103.09K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 874.10K | 506.57K | 399.38K | 400.00K | 500.00K | 500.00K | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 135.00K | 268.00K | 87.00K | 201.00K | 240.00K | 272.00K | 245.00K | 157.00K | 72.00K | 0.00 | 0.00 | 0.00 | 0.00 | 467.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 118.78K | 86.34K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 | 100.00K |
| Gross Profit | -135.00K | -268.00K | -87.00K | -201.00K | -240.00K | -272.00K | -245.00K | -157.00K | -72.00K | 0.00 | 0.00 | 0.00 | 0.00 | 2.70M | 103.09K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 874.10K | 387.80K | 313.04K | 300.00K | 400.00K | 400.00K | 100.00K | 100.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.22% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 76.55% | 78.38% | 75.00% | 80.00% | 80.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 14.31M | 11.72M | 7.80M | 5.13M | 11.08M | 11.84M | 18.78M | 29.11M | 32.91M | 14.49M | 6.51M | 12.29M | 3.34M | 1.58M | 1.20M | 4.64M | 6.33M | 2.67M | 946.07K | 3.62M | 6.00M | 3.75M | 3.42M | 2.40M | 5.40M | 0.00 | 4.40M | 0.00 | 0.00 |
| General & Administrative | 7.16M | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M | 7.47M | 10.14M | 8.07M | 6.01M | 5.07M | 5.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 624.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 763.00K | 5.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.78M | 9.86M | 6.47M | 5.03M | 4.58M | 5.73M | 7.47M | 10.14M | 8.07M | 6.01M | 5.83M | 5.01M | 2.59M | 2.70M | 2.58M | 2.68M | 3.81M | 1.44M | 285.70K | 4.48M | 4.55M | 2.82M | 2.28M | 3.00M | 4.60M | 7.70M | 3.00M | 6.40M | 3.60M |
| Other Expenses | -660.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.43M | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M | 26.25M | 39.25M | 40.98M | 20.50M | 12.34M | 17.30M | 5.93M | 4.28M | 3.78M | 7.32M | 10.14M | 4.10M | 1.32M | 8.26M | 10.68M | 6.68M | 5.79M | 5.50M | 10.10M | 7.80M | 7.40M | 6.40M | 3.70M |
| Cost & Expenses | 21.43M | 21.58M | 14.27M | 10.16M | 15.66M | 17.57M | 26.25M | 39.25M | 40.98M | 20.50M | 12.34M | 17.30M | 5.93M | 4.75M | 3.78M | 7.32M | 10.14M | 4.10M | 1.32M | 8.26M | 10.68M | 6.80M | 5.87M | 5.60M | 10.20M | 7.90M | 7.40M | 6.40M | 3.80M |
| Interest Income | 1.44M | 512.00K | 6.00K | 44.00K | 283.00K | 67.00K | 21.00K | 37.00K | 6.00K | 3.00K | 33.00K | 33.00K | 14.00K | 413.00 | 2.97K | 128.24K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.11K | 9.88K | 13.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 135.00K | 268.00K | 87.00K | 201.00K | 240.00K | 272.00K | 245.00K | 157.00K | 72.00K | 20.00K | 43.00K | 63.00K | 201.00K | 358.71K | 382.09K | 404.62K | 199.63K | 30.68K | 2.26K | -154.13K | -130.55K | -118.78K | -86.34K | -100.00K | -100.00K | -100.00K | 0.00 | 0.00 | -100.00K |
| EBITDA | -19.85M | -21.58M | -14.19M | -9.96M | -15.42M | -17.30M | -26.01M | -39.10M | -40.91M | -20.48M | -11.53M | -17.22M | -7.48M | -1.22M | -3.34M | -6.91M | -9.94M | -4.07M | -1.28M | -8.09M | -9.76M | -6.42M | -5.39M | -5.15M | -7.90M | -7.40M | -7.30M | -6.30M | -3.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38.71% | -3,158.80% | 0.00% | 0.00% | 0.00% | 0.00% | -80,946.53% | -1,116.24% | -1,266.71% | 2,407.29% | 2,025.00% | -1,940.00% | -1,480.00% | -7,300.00% | -6,400.00% | -3,500.00% |
| Operating Income | -21.43M | -21.58M | -14.27M | -10.16M | -15.66M | -17.57M | -26.25M | -39.25M | -40.98M | -20.50M | -12.34M | -17.30M | -5.93M | -1.58M | -3.68M | -7.32M | -10.14M | -4.12M | -1.36M | -8.09M | -9.68M | -6.30M | 9.70M | 8.20M | -9.60M | -7.30M | -7.30M | -6.40M | -3.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -50.05% | -3,571.17% | 0.00% | 0.00% | 0.00% | 0.00% | -80,946.53% | -1,107.12% | -1,243.26% | 2,428.90% | 2,050.00% | -1,920.00% | -1,460.00% | -7,300.00% | -6,400.00% | -3,400.00% |
| Total Other Income/Expenses | 1.44M | 471.00K | 6.00K | 44.00K | 283.00K | 4.15M | 10.76M | 11.45M | -3.81M | 718.00K | 21.00K | 15.00K | -1.70M | -127.21K | -43.01K | -357.00 | 245.88K | -12.50K | 1.34M | 0.00 | 79.71K | 237.55K | 172.68K | 250.00K | -1.50M | 100.00K | 7.30M | 0.00 | 200.00K |
| Income Before Tax | -19.99M | -21.11M | -14.27M | -10.12M | -15.38M | -13.42M | -15.49M | -27.80M | -44.79M | -19.78M | -12.32M | -17.28M | -7.63M | -1.71M | -3.72M | -7.32M | 0.00 | -4.13M | -1.39M | 0.00 | -9.60M | -6.06M | -5.30M | -5.00M | -9.50M | -7.20M | 0.00 | -6.30M | -3.50M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -54.07% | -3,612.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,098.00% | -1,195.96% | -1,326.94% | -1,250.00% | -1,900.00% | -1,440.00% | 0.00% | -6,300.00% | -3,500.00% |
| Income Tax Expense | -1.64M | -1.43M | -94.00K | -117.00K | -360.00K | -4.20M | -11.08M | -12.00M | 2.76M | -718.00K | -22.00K | -231.00K | 2.22M | 10.11K | 49.93K | -114.05K | -245.88K | -5.48K | 36.63K | 677.06K | -67.57K | -295.25K | 12.09M | 13.60M | 0.00 | -200.00K | 7.40M | 0.00 | 400.00K |
| Net Income | -18.35M | -19.69M | -14.17M | -10.00M | -15.02M | -13.37M | -15.17M | -27.26M | -43.74M | -19.78M | -12.32M | -17.07M | -8.15M | -1.71M | -3.73M | -7.21M | -9.89M | -4.10M | -1.36M | -8.62M | -9.48M | -5.76M | -17.38M | -18.60M | -9.50M | -7.00M | -7.40M | -6.30M | -3.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -54.07% | -3,619.60% | 0.00% | 0.00% | 0.00% | 0.00% | -86,175.82% | -1,084.45% | -1,137.68% | -4,352.97% | -4,650.00% | -1,900.00% | -1,400.00% | -7,400.00% | -6,300.00% | -3,900.00% |
| EPS | -28.49 | -32.11 | -1.16 | -5.26 | -9.14 | -21.45 | -42.70 | -101.17 | -189.68 | -111.78 | -94.40 | -171.19 | -102.93 | -26.75 | -61.26 | -122.12 | -196.76 | -442.24 | -982.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -28.48 | -32.11 | -1.16 | -5.26 | -9.14 | -21.45 | -42.70 | -101.17 | -189.68 | -111.78 | -94.40 | -171.19 | -102.93 | -26.75 | -61.26 | -122.12 | -196.76 | -442.24 | -982.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 644.00K | 613.09K | 12.19M | 1.90M | 1.64M | 623.24K | 355.33K | 269.40K | 230.58K | 176.98K | 130.48K | 99.70K | 79.17K | 63.98K | 60.91K | 59.00K | 50.28K | 9.27K | 1.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 644.28K | 613.09K | 12.19M | 1.90M | 1.64M | 623.24K | 355.33K | 269.40K | 230.58K | 176.98K | 130.48K | 99.70K | 79.17K | 63.98K | 60.91K | 59.00K | 50.28K | 9.27K | 1.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript
Theriva Biologics, Inc. (NYSE:TOVX ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Steve Shallcross - Chief Executive and CFO Dr. Manel Cascalló - General Director, European Subsidiary Dr. Vince Wacher - Head, Corporate and...
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of VCN-01, which continues...
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results
ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a...
Theriva™ Biologics to Participate in the BIO-Europe Conference
ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's Management will provide a...
Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer
- Theriva signs exclusive option to license intellectual property from Sant Joan de Déu-Barcelona Children's Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisomerase I inhibitors -
Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023
-Results show enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies-
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
-Results from investigator-sponsored study in collaboration with the Institut Catala d'Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1-
Theriva Biologics to Participate in the Emerging Growth Conference
ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's Management will provide a...
Theriva Biologics, Inc. (TOVX) Q2 2023 Earnings Call Transcript
Theriva Biologics, Inc. (NYSE:TOVX ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Chris Calabrese - IR, LifeSci Advisors Steven Shallcross - Chief Executive and CFO Dr. Manel Cascalló - General Director Dr. Vince Wacher...
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma
Source: https://incomestatements.info
Category: Stock Reports